Berenberg Bank Downgrades Evotec (NASDAQ:EVO) to Hold

Evotec (NASDAQ:EVO) was downgraded by Berenberg Bank from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, MarketBeat reports.

EVO has been the topic of several other research reports. Weiss Ratings raised Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. TD Cowen cut Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a report on Wednesday. HC Wainwright cut their target price on shares of Evotec from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Wall Street Zen lowered shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $3.00.

Evotec Price Performance

EVO opened at $1.96 on Thursday. Evotec has a one year low of $1.95 and a one year high of $4.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.68 and a quick ratio of 1.60. The company’s 50 day simple moving average is $2.75 and its 200-day simple moving average is $3.01.

Hedge Funds Weigh In On Evotec

Hedge funds have recently added to or reduced their stakes in the stock. ABC Arbitrage SA boosted its stake in Evotec by 319.7% during the 4th quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock worth $1,707,000 after acquiring an additional 422,230 shares during the last quarter. Marshall Wace LLP bought a new stake in Evotec in the fourth quarter valued at approximately $40,000. HRT Financial LP bought a new stake in Evotec in the fourth quarter valued at approximately $72,000. Goldman Sachs Group Inc. acquired a new stake in Evotec in the fourth quarter worth $110,000. Finally, BNP Paribas Financial Markets raised its holdings in Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after purchasing an additional 4,600 shares during the period. Institutional investors and hedge funds own 5.81% of the company’s stock.

Key Headlines Impacting Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Evotec AG and kept its $4.00 price target, signaling some confidence in longer-term upside.
• Neutral Sentiment: Analysts still expect Evotec to remain loss-making in the near term, with forecast EPS revisions showing only a gradual path toward profitability. Evotec AG stock page
• Negative Sentiment: HC Wainwright cut its Q3 2026 EPS estimate to ($0.04) from ($0.01), implying weaker-than-expected near-term earnings momentum.
• Negative Sentiment: The firm also lowered its Q4 2026 EPS forecast to ($0.02), reduced FY2026 EPS to ($0.31), and trimmed FY2027 EPS to $0.07, reinforcing concerns about slower earnings recovery.
• Negative Sentiment: Separately, Berenberg Bank downgraded Evotec from Buy to Hold, which likely added to the stock’s weakness by signaling less conviction in the near-term setup.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.